RESUMEN
The synthesis and bioactivity of the retinoid X receptor (RXR) antagonist 4-[(3'-n-butyl-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'-naphthalenyl)(cyclopropylidene)methyl]benzoic acid and several heteroatom-substituted analogues are described. Ligand design was based on the scaffold of the 3'-methyl RXR-selective agonist analogue and reports that 3'-n-propyl and longer n-alkyl groups conferred RXR antagonism. The transcriptional antagonism of the 3'-n-butyl analogue was demonstrated by its blockade of retinoic acid receptor (RAR) beta expression induced by the RXRalpha/peroxisome proliferator-activated receptor (PPAR) gamma heterodimer complexed with an RXRalpha agonist plus the PPARgamma agonist ciglitazone and the inhibition of 9-cis-RA-induced coactivator SRC-1a recruitment to RXRalpha. Receptor-ligand docking studies using full-atom flexible ligand and flexible receptor suggested that binding of the antagonist to the RXRalpha antagonist conformation was favored because the salt bridge that formed between the retinoid carboxylate and the RXRalpha helix H5 arginine-321 was far stronger than that formed on its binding to the agonist conformation. The antagonist also blocked activation of RAR subtypes alpha and beta by 9-cis-RA but not that of RARgamma.
Asunto(s)
Diseño de Fármacos , Receptores de Ácido Retinoico/antagonistas & inhibidores , Retinoides/síntesis química , Retinoides/farmacología , Factores de Transcripción/antagonistas & inhibidores , Transcripción Genética/efectos de los fármacos , Benzoatos/síntesis química , Benzoatos/química , Benzoatos/farmacología , Sitios de Unión , Simulación por Computador , Humanos , Ligandos , Docilidad , Unión Proteica , Conformación Proteica , Receptores de Ácido Retinoico/fisiología , Receptores X Retinoide , Retinoides/química , Electricidad Estática , Relación Estructura-Actividad , Factores de Transcripción/fisiologíaRESUMEN
The retinoid 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) and its active analogues induce cell-cycle arrest and programmed cell death (apoptosis) in cancer cells independently of retinoic acid receptor (RAR) interaction. Its analogue, (E)-4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-(3'-acetamidopropyloxy)cinnamic acid (3-A-AHPC) selectively antagonized cell apoptotic events (TR3/nur77/NGFI-B expression and nuclear-to-mitochondrial translocation) but not the proliferative events (cell-cycle arrest and p21(WAF1/CIP1) expression) induced by proapoptotic AHPN and its analogues. The syntheses of 3-A-AHPC and proapoptotic (E)-6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-5-chloronaphthalenecarboxylic acid (5-Cl-AHPN) are described. Computational studies on AHPN, AHPC, and three substituted analogues (5-Cl-AHPN, 3-Cl-AHPC, and 3-A-AHPC) suggested reasons for their diametric effects on RAR activation. Density functional theory studies indicated that the 1-adamantyl (1-Ad) groups of the AHPN and AHPC configurations assumed positions that were nearly planar with the aromatic rings of their polar termini. In contrast, in the configurations of the substituted analogues having chloro and 3-acetamidopropyloxy groups, rather than a hydrogen, ortho to the diaryl bonds, the diaryl bond torsion angles increased so that the 1-Ad groups were oriented out of this plane. Docking and molecular dynamics of AHPN, AHPC, and these substituted analogues in the RARgamma ligand-binding domain illustrated how specific substituents on the AHPN and AHPC scaffolds modulated the positions and dynamics of the 1-Ad groups. As a result, the position of RARgamma helix H12 in forming the coactivator-binding site was impacted in a manner consistent with the experimental effect of each analogue on RARgamma transcriptional activation.
Asunto(s)
Adamantano/síntesis química , Antineoplásicos/síntesis química , Apoptosis/efectos de los fármacos , Cinamatos/síntesis química , Naftalenos/síntesis química , Adamantano/análogos & derivados , Adamantano/química , Adamantano/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Unión Competitiva , División Celular/efectos de los fármacos , Línea Celular Tumoral , Cinamatos/química , Cinamatos/farmacología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/biosíntesis , Diseño de Fármacos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Ligandos , Modelos Moleculares , Conformación Molecular , Naftalenos/química , Naftalenos/farmacología , Relación Estructura-Actividad Cuantitativa , Receptores Citoplasmáticos y Nucleares/metabolismo , Receptores de Ácido Retinoico/metabolismo , Receptores X Retinoide , Factores de Transcripción/metabolismo , Activación TranscripcionalRESUMEN
OBJECTIVE: The purpose of this study was to determine the intrarater and interrater reliability of the Balance Error Scoring System (BESS). DESIGN: A prospective observational study. SETTING: Academic sports medicine center. PARTICIPANTS: Three scorers participated in this study. METHODS: Three scorers experienced in using the BESS viewed a videotape depicting 30 consecutive individuals performing the BESS stance positions. The 3 scorers independently scored each of the 30 videotaped individuals using the BESS scoring criteria. A week later, the same 3 subjects viewed and scored the videotape again. MAIN OUTCOME MEASUREMENTS: The interrater and intrarater reliability of the BESS was determined using intraclass correlation coefficients (ICC), reported with 95% confidence intervals. The minimum detectible change was also determined. RESULTS: The interrater and intrarater reliability ICCs for the total BESS scores were 0.57 and 0.74, respectively. The interrater reliability ICCs for the 6 different stance positions were between 0.44 and 0.83, while the intrarater reliability ICCs were between 0.50 and 0.88. The interrater and intrarater minimum detectible change for the total BESS score were 9.4 and 7.3 points, respectively. CONCLUSION: This study suggests that certain subcategories of the BESS have sufficient reliability to be used in the evaluation of postural stability but that the total BESS score is not reliable. In addition, a change in score of greater than 9.4 (interrater) or 7.3 (intrarater) points is required before the change in postural stability can be attributed to the balancer rather than to the scorer.
Asunto(s)
Equilibrio Postural , Trastornos de la Sensación/diagnóstico , Índice de Severidad de la Enfermedad , Conmoción Encefálica/complicaciones , Humanos , Variaciones Dependientes del Observador , Estudios Prospectivos , Trastornos de la Sensación/etiologíaRESUMEN
Chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2 (CTIP2), also known as Bcl11b, is a transcriptional repressor that functions by direct, sequence-specific DNA binding activity or by recruitment to the promoter template by interaction with COUP-TF family members. CTIP2 is essential for both T cell development and axonal projections of corticospinal motor neurons in the central nervous system. However, little is known regarding the molecular mechanism(s) by which CTIP2 contributes to either process. CTIP2 complexes that were isolated from SK-N-MC neuroblastoma cells were found to harbor substantial histone deacetylase activity, which was likely conferred by the nucleosome remodeling and deacetylation (NuRD) complex. CTIP2 was found to associate with the NuRD complex through direct interaction with both RbAp46 and RbAp48, and components of the NuRD complex were found to be recruited to an artificial promoter template in a CTIP2-dependent manner in transfected cells. Finally, the NuRD complex and CTIP2 were found to co-occupy the promoter template of p57KIP2, a gene encoding a cyclin-dependent kinase inhibitor, and identified herein as a novel transcriptional target of CTIP2 in SK-N-MC cells. Therefore, it seems likely that the NuRD complex may be involved in transcriptional repression of CTIP2 target genes and contribute to the function(s) of CTIP2 within a neuronal context.
Asunto(s)
Factor de Transcripción COUP II/genética , Factor de Transcripción COUP II/metabolismo , Inhibidor p57 de las Quinasas Dependientes de la Ciclina/genética , Histona Desacetilasas/metabolismo , Regiones Promotoras Genéticas , Sitios de Unión , Técnicas de Cultivo de Célula , Línea Celular , Inmunoprecipitación de Cromatina , Inhibidores Enzimáticos/farmacología , Genes Reporteros , Glutatión Transferasa/metabolismo , Humanos , Ácidos Hidroxámicos/farmacología , Luciferasas/metabolismo , Complejo Desacetilasa y Remodelación del Nucleosoma Mi-2 , Neuroblastoma/metabolismo , Neuroblastoma/patología , Unión Proteica , Proteínas Recombinantes de Fusión/metabolismo , TransfecciónRESUMEN
The B cell leukemia 11A protein (BCL11A/Evi9/CTIP1) has been implicated in hematopoietic cell development and malignancies. BCL11A is a transcriptional repressor that binds directly to a GC-rich motif and is also recruited to a promoter template via interaction with the orphan nuclear receptor, chicken ovalbumin upstream promoter transcription factor II. In both cases, BCL11A-mediated transcriptional repression is only minimally reversed by trichostatin A, suggesting the possible lack of involvement of class I or II histone deacetylases. Nonetheless, chromatin immunoprecipitation assays revealed that expression of BCL11A in mammalian cells resulted in deacetylation of histones H3 and/or H4 that were associated with the promoter region of a reporter gene. BCL11A-mediated transcriptional repression, as well as deacetylation of histone H3/H4 in BCL11A-transfected cells, was partially reversed by nicotinamide, an inhibitor of class III histone deacetylases such as SIRT1. SIRT1 was found to interact directly with BCL11A and was recruited to the promoter template in a BCL11A-dependent manner leading to transcriptional repression. These findings define a role for SIRT1 in transcriptional repression mediated by BCL11A in mammalian cells.
Asunto(s)
Proteínas Portadoras/fisiología , Histona Desacetilasas/metabolismo , Histonas/química , Proteínas Nucleares/fisiología , Regiones Promotoras Genéticas , Sirtuinas/metabolismo , Transcripción Genética , Secuencias de Aminoácidos , Animales , Proteínas Portadoras/metabolismo , Línea Celular , Inmunoprecipitación de Cromatina , Eliminación de Gen , Genes Reporteros , Glutatión Transferasa/metabolismo , Humanos , Ácidos Hidroxámicos/farmacología , Inmunoprecipitación , Modelos Genéticos , Niacinamida/química , Niacinamida/farmacología , Proteínas Nucleares/metabolismo , Unión Proteica , Estructura Terciaria de Proteína , Proteínas Represoras , Sirtuina 1 , TransfecciónRESUMEN
Chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting proteins 1 and 2 (CTIP1 and CTIP2) enhance transcriptional repression mediated by COUP-TF II and have been implicated in hematopoietic cell development and malignancies. CTIP1 and CTIP2 are also sequence-specific DNA-binding proteins that repress transcription through direct, COUP-TF-in-dependent binding to a GC-rich response element. CTIP1- and CTIP2-mediated transcriptional repression is insensitive to trichostatin A, an inhibitor of known class I and II histone deacetylases. However, chromatin immunoprecipitation assays revealed that expression of CTIP2 in mammalian cells resulted in deacetylation of histones H3 and/or H4 that were associated with the promoter region of a reporter gene. CTIP2-mediated transcriptional repression, as well as deacetylation of promoter-associated histones H3/H4 in CTIP2-transfected cells, was reversed by nicotinamide, an inhibitor of class III histone deacetylases such as the mammalian homologs of yeast Silent Information Regulator 2 (Sir2). The human homolog of yeast Sir2, SIRT1, was found to interact directly with CTIP2 and was recruited to the promoter template in a CTIP2-dependent manner. Moreover, SIRT1 enhanced the deacetylation of template-associated histones H3/H4 in CTIP2-transfected cells, and stimulated CTIP2-dependent transcriptional repression. Finally, endogenous SIRT1 and CTIP2 co-purified from Jurkat cell nuclear extracts in the context of a large (1-2 mDa) complex. These findings implicate SIRT1 as a histone H3/H4 deacetylase in mammalian cells and in transcriptional repression mediated by CTIP2.
Asunto(s)
Proteínas Portadoras , Proteínas de Unión al ADN/metabolismo , Proteínas de Unión al ADN/fisiología , Histona Desacetilasas/fisiología , Proteínas Nucleares , Receptores de Esteroides , Proteínas Represoras/fisiología , Sirtuinas/fisiología , Factores de Transcripción/metabolismo , Factores de Transcripción COUP , Línea Celular , Núcleo Celular/metabolismo , Cromatina/metabolismo , ADN/metabolismo , Proteínas de Unión al ADN/química , Inhibidores Enzimáticos/farmacología , Silenciador del Gen , Genes Reporteros , Glutatión Transferasa/metabolismo , Histona Desacetilasas/metabolismo , Humanos , Ácidos Hidroxámicos/farmacología , Immunoblotting , Células Jurkat , NAD/metabolismo , Proteínas de Neoplasias/química , Proteínas de Neoplasias/fisiología , Niacinamida/farmacología , Pruebas de Precipitina , Unión Proteica , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Represoras/química , Sirtuina 1 , Sirtuinas/metabolismo , Transcripción Genética , Transfección , Proteínas Supresoras de TumorRESUMEN
Apo and holo forms of retinoic acid receptors, and other nuclear receptors, display differential sensitivity to proteolytic digestion that likely reflects the distinct conformational states of the free and liganded forms of the receptor. We have developed a method for rapid peptide mapping of holo-retinoic acid receptor gamma that utilizes matrix-assisted laser-desorption-ionization time-of-flight MS to identify peptide fragments that are derived from the partially proteolysed holo-receptor. The peptide maps of retinoic acid receptor gamma bound by four different agonists were identical, suggesting that all four ligands induced a similar conformational change within the ligand-binding domain of the receptor. In all cases, this agonist-induced conformational change promoted the direct association of retinoic acid receptor gamma with the transcriptional co-activator p300 and inhibited interaction of the receptor with the nuclear receptor co-repressor. SR11253, a compound previously reported to exert mixed retinoic acid receptor gamma agonist/antagonist activities in cultured cells, was found to bind directly to, but only weakly altered the protease-sensitivity of, the receptor and failed to promote interaction of the receptor with p300 or induce dissociation of receptor-nuclear receptor co-repressor complexes. This technique should be generally applicable to other members of the nuclear receptor superfamily that undergo an induced structural alteration upon agonist or antagonist binding, DNA binding and/or protein-protein interaction.
Asunto(s)
Receptores de Ácido Retinoico/química , Secuencia de Aminoácidos , Compuestos Heterocíclicos/farmacología , Modelos Moleculares , Datos de Secuencia Molecular , Proteínas Nucleares/metabolismo , Unión Proteica , Conformación Proteica , Receptores de Ácido Retinoico/agonistas , Receptores de Ácido Retinoico/metabolismo , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Transactivadores/metabolismo , Receptor de Ácido Retinoico gammaRESUMEN
Acute myelogenous leukemia (AML) is a heterogeneous disease consisting of a variety of different leukemic subtypes. While acute promyelocytic leukemia displays marked sensitivity to the differentiating effects of trans-retinoic acid (tRA), other subtypes of AML display resistance. We now describe a novel compound (E)-4-[3-(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3-Cl-AHPC/MM002) that induces apoptosis in the tRA-resistant leukemia cell lines M07e, KG-1, and HL-60R, and in tRA-resistant patient leukemic blasts. The 3-Cl-AHPC totally inhibits leukemia colony formation at concentrations that inhibit committed human bone marrow stem cell proliferation, that is, granulocyte/macrophage colony-forming units (CFU-GMs) by only 30%. Exposure to 3-Cl-AHPC results in caspase activation and the cleavage of poly(adenosine diphosphate) (poly(ADP)) ribose polymerase. While activation of the extracellular signal-regulated kinase (ERK) and p38 pathways is not necessary for 3-Cl-AHPC-mediated apoptosis, maximal apoptosis requires c-Jun N-terminal kinase (JNK) activation. The 3-Cl-AHPC-mediated cleavage of the antiapoptotic B-cell leukemia XL (Bcl-XL) protein to a proapoptotic 18-kDa product is found in both the M07e cell line and patient leukemic blasts. The 3-Cl-AHPC treatment of mice bearing the AML 1498 cell line results in a 3.3-log kill in the leukemic blasts. While 3-Cl-AHPC does not activate retinoic nuclear receptors, it is a potent inducer of apoptosis in AML cells and may represent a novel therapy in the treatment of this disease.